FR18C1008I2 - Regime posologique de cladribine pour le traitement de la sclerose en plaques - Google Patents

Regime posologique de cladribine pour le traitement de la sclerose en plaques

Info

Publication number: FR18C1008I2
Authority: FR; France
Prior art keywords: cladribine; treatment; multiple sclerosis; dosage regimen; regimen
Prior art date: 2004-12-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

FR18C1008C

Other languages

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Merck Serono SA

Original Assignee

Merck Serono SA

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-12-22

Filing date

2018-02-14

Publication date

2019-03-01

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36227798&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR18C1008(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2018-02-14 Application filed by Merck Serono SA filed Critical Merck Serono SA

2018-03-30 Publication of FR18C1008I1 publication Critical patent/FR18C1008I1/fr

2019-03-01 Application granted granted Critical

2019-03-01 Publication of FR18C1008I2 publication Critical patent/FR18C1008I2/fr

Status Active legal-status Critical Current

Links

PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 title 1
229960002436 cladribine Drugs 0.000 title 1
201000006417 multiple sclerosis Diseases 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Molecular Biology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

FR18C1008C 2004-12-22 2018-02-14 Regime posologique de cladribine pour le traitement de la sclerose en plaques Active FR18C1008I2 (fr)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US63866904P	2004-12-22	2004-12-22
EP04106909		2004-12-22
EP05823474A EP1827461B1 (fr)	2004-12-22	2005-12-20	Régime posologique de cladribine pour le traitement de la sclérose en plaques
PCT/EP2005/056954 WO2006067141A1 (fr)	2004-12-22	2005-12-20	Schema posologique a base de cladribine destine a traiter la sclerose en plaques

Publications (2)

Publication Number	Publication Date
FR18C1008I1 FR18C1008I1 (fr)	2018-03-30
FR18C1008I2 true FR18C1008I2 (fr)	2019-03-01

Family

ID=36227798

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FR18C1008C Active FR18C1008I2 (fr)	2004-12-22	2018-02-14	Regime posologique de cladribine pour le traitement de la sclerose en plaques

Country Status (25)

Country	Link
US (2)	US7713947B2 (fr)
EP (7)	EP2275110B1 (fr)
JP (7)	JP5795456B2 (fr)
KR (1)	KR20070091662A (fr)
AR (1)	AR052830A1 (fr)
AU (2)	AU2005318190B2 (fr)
BR (1)	BRPI0517132B8 (fr)
CA (2)	CA2588966C (fr)
CY (3)	CY1112614T1 (fr)
DK (3)	DK3332789T3 (fr)
EA (1)	EA015799B1 (fr)
ES (2)	ES2921858T3 (fr)
FI (1)	FI4070800T3 (fr)
FR (1)	FR18C1008I2 (fr)
HR (1)	HRP20120228T1 (fr)
HU (3)	HUE059133T2 (fr)
IL (2)	IL183930A0 (fr)
LT (3)	LT3332789T (fr)
LU (1)	LUC00064I2 (fr)
MX (1)	MX2007007610A (fr)
NO (1)	NO20073813L (fr)
PL (4)	PL2805723T3 (fr)
SG (1)	SG160391A1 (fr)
SI (3)	SI2805723T1 (fr)
WO (1)	WO2006067141A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL2805723T3 (pl)	2004-12-22	2018-04-30	Merck Serono Sa	Schemat dawkowania kladrybiny dla leczenia stwardnienia rozsianego
MX2008014971A (es) *	2006-05-24	2008-12-05	Serono Lab	Regimen de cladribine para tratar esclerosis multiple.
EP2343074A1 (fr)	2009-12-23	2011-07-13	Merck Serono S.A.	Utilisation d'analogues de la purine pour traiter des maladies des voies respiratoires
WO2011117267A1 (fr)	2010-03-24	2011-09-29	Merck Serono Sa	Traitement à la cladribine de la sclérose en plaques chez des groupes de patients définis par génotype
EP2428201A1 (fr)	2010-09-08	2012-03-14	Merck Serono S.A.	Administration orale de nucléosides monophosphates
WO2012097867A1 (fr)	2011-01-18	2012-07-26	Synthon Bv	Particules de cladribine et compositions pharmaceutiques comprenant celles-ci
GB201401465D0 (en)	2014-01-29	2014-03-12	Roach Arthur H	Use of cladribine for treating autoimmune inflammatory disease
GB2564717A (en)	2017-07-21	2019-01-23	Chord Therapeutics S A R L	Use of cladribine for treating autoimmune neuromuscular disease
AR113906A1 (es) *	2017-11-24	2020-06-24	Merck Patent Ges Mit Beschraenkter Haftung	Régimen con cladribina para tratar formas progresivas de la esclerosis múltiple
IL301246A (en)	2020-09-10	2023-05-01	Merck Patent Gmbh	Treatment regimen with cladribine
GB2601786A (en)	2020-12-10	2022-06-15	Chord Therapeutics S A R L	Use of cladribine for treating immune brain disease

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1269659A (fr)	1984-08-06	1990-05-29	Brigham Young University	Preparation de composes a base de 2'-desoxyadenosine
US5310732A (en)	1986-02-03	1994-05-10	The Scripps Research Institute	2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US4964848A (en) *	1988-06-27	1990-10-23	Bloom Philip M	Treatment of multiple sclerosis with lymphocytapheresis and chemo-immunosuppression
US5208327A (en)	1991-12-18	1993-05-04	Ortho Pharmaceutical Corporation	Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine
US5641757A (en)	1994-12-21	1997-06-24	Ortho Pharmaceutical Corporation	Stable 2-chloro-2'-deoxyadenosine formulations
PL321431A1 (en)	1994-12-22	1997-12-08	Ortho Pharma Corp	Soluble 2-chloro-2'deoxyadenosine compositions
US6194395B1 (en)	1999-02-25	2001-02-27	Orthro-Mcneil Pharmaceutical, Inc.	Cyclodextrin cladribine formulations
WO2000064918A1 (fr)	1999-04-28	2000-11-02	Sterrenbeld Biotechnologie North America, Inc.	Procede de production de 2-chloro-2'-desoxyadenosine (cladribine) et son derive 3,5-di-o-p-toluoyle
DE10237146A1 (de) *	2002-08-13	2004-03-04	Medac Gesellschaft für klinische Spezialpräparate mbH	Verwendung von Treosulfan und Derivaten davon zur Behandlung der Multiplen Sklerose
WO2004028462A2 (fr)	2002-09-25	2004-04-08	Brigham Young University, Technology Transfer Office	Procede de preparation de composes de 2-halo-2'-deoxyadenosine a partir de 2'-deoxyguanosine
GB2394658A (en) *	2002-11-01	2004-05-05	Cancer Rec Tech Ltd	Oral anti-cancer composition
BRPI0407781A (pt) *	2003-02-25	2006-02-14	Applied Research Systems	aplicação combinada de ribavirina e interferon beta em doenças desmielinizantes
WO2004087101A2 (fr)	2003-03-28	2004-10-14	Ivax Corporation	Formulations de cladribine a administration par voie orale
ES2584183T3 (es)	2003-03-28	2016-09-26	Ares Trading S.A.	Formulaciones de cladribina para suministro mejorado oral y transmucosa
PL2805723T3 (pl)	2004-12-22	2018-04-30	Merck Serono Sa	Schemat dawkowania kladrybiny dla leczenia stwardnienia rozsianego
MX2008014971A (es) *	2006-05-24	2008-12-05	Serono Lab	Regimen de cladribine para tratar esclerosis multiple.

2005
- 2005-12-20 PL PL14001970T patent/PL2805723T3/pl unknown
- 2005-12-20 EP EP10182632.9A patent/EP2275110B1/fr not_active Expired - Lifetime
- 2005-12-20 HU HUE18151634A patent/HUE059133T2/hu unknown
- 2005-12-20 CA CA2588966A patent/CA2588966C/fr not_active Expired - Lifetime
- 2005-12-20 LT LTEP18151634.5T patent/LT3332789T/lt unknown
- 2005-12-20 PL PL22166610.0T patent/PL4070800T3/pl unknown
- 2005-12-20 EA EA200701221A patent/EA015799B1/ru active Protection Beyond IP Right Term
- 2005-12-20 EP EP14001970.4A patent/EP2805723B1/fr not_active Revoked
- 2005-12-20 HR HR20120228T patent/HRP20120228T1/hr unknown
- 2005-12-20 PL PL05823474T patent/PL1827461T3/pl unknown
- 2005-12-20 SI SI200532191T patent/SI2805723T1/en unknown
- 2005-12-20 ES ES18151634T patent/ES2921858T3/es not_active Expired - Lifetime
- 2005-12-20 EP EP22166610.0A patent/EP4070800B1/fr not_active Revoked
- 2005-12-20 EP EP05823474A patent/EP1827461B1/fr not_active Expired - Lifetime
- 2005-12-20 KR KR1020077016508A patent/KR20070091662A/ko not_active Ceased
- 2005-12-20 SI SI200532321T patent/SI4070800T1/sl unknown
- 2005-12-20 BR BRPI0517132A patent/BRPI0517132B8/pt active IP Right Grant
- 2005-12-20 EP EP18151634.5A patent/EP3332789B1/fr not_active Expired - Lifetime
- 2005-12-20 PL PL18151634.5T patent/PL3332789T3/pl unknown
- 2005-12-20 DK DK18151634.5T patent/DK3332789T3/da active
- 2005-12-20 US US11/722,018 patent/US7713947B2/en active Active
- 2005-12-20 JP JP2007547486A patent/JP5795456B2/ja not_active Expired - Lifetime
- 2005-12-20 WO PCT/EP2005/056954 patent/WO2006067141A1/fr not_active Ceased
- 2005-12-20 EP EP24206496.2A patent/EP4523753A3/fr not_active Withdrawn
- 2005-12-20 ES ES22166610T patent/ES3007339T3/es not_active Expired - Lifetime
- 2005-12-20 DK DK14001970.4T patent/DK2805723T3/da active
- 2005-12-20 MX MX2007007610A patent/MX2007007610A/es unknown
- 2005-12-20 DK DK22166610.0T patent/DK4070800T3/da active
- 2005-12-20 LT LTEP22166610.0T patent/LT4070800T/lt unknown
- 2005-12-20 HU HUE22166610A patent/HUE070333T2/hu unknown
- 2005-12-20 CA CA3087419A patent/CA3087419C/fr not_active Expired - Lifetime
- 2005-12-20 SG SG201001736-6A patent/SG160391A1/en unknown
- 2005-12-20 SI SI200532305T patent/SI3332789T1/sl unknown
- 2005-12-20 FI FIEP22166610.0T patent/FI4070800T3/fi active
- 2005-12-20 EP EP10182676.6A patent/EP2263678B1/fr not_active Expired - Lifetime
- 2005-12-20 AU AU2005318190A patent/AU2005318190B2/en not_active Expired
- 2005-12-21 AR ARP050105411A patent/AR052830A1/es not_active Application Discontinuation
2007
- 2007-06-14 IL IL183930A patent/IL183930A0/en active IP Right Grant
- 2007-07-20 NO NO20073813A patent/NO20073813L/no not_active Application Discontinuation
2010
- 2010-04-23 US US12/766,173 patent/US8377903B2/en not_active Expired - Lifetime
2011
- 2011-02-23 AU AU2011200768A patent/AU2011200768B2/en not_active Expired
- 2011-04-17 IL IL212421A patent/IL212421A/en active IP Right Grant
2012
- 2012-04-11 CY CY20121100358T patent/CY1112614T1/el unknown
2013
- 2013-05-30 JP JP2013113850A patent/JP5908863B2/ja not_active Expired - Lifetime
2015
- 2015-06-16 JP JP2015120875A patent/JP6092945B2/ja not_active Expired - Lifetime
2016
- 2016-04-08 JP JP2016078293A patent/JP6290962B2/ja not_active Expired - Lifetime
2017
- 2017-02-09 JP JP2017022375A patent/JP6430554B2/ja not_active Expired - Lifetime
2018
- 2018-01-18 CY CY20181100065T patent/CY1119790T1/el unknown
- 2018-02-12 LU LU00064C patent/LUC00064I2/fr unknown
- 2018-02-14 FR FR18C1008C patent/FR18C1008I2/fr active Active
- 2018-02-15 HU HUS1800009C patent/HUS1800009I1/hu unknown
- 2018-02-20 LT LTPA2018503C patent/LTC2805723I2/lt unknown
- 2018-02-28 CY CY2018006C patent/CY2018006I2/el unknown
- 2018-07-09 JP JP2018129918A patent/JP2018165271A/ja active Pending
2020
- 2020-08-06 JP JP2020134010A patent/JP2020193206A/ja active Pending

Also Published As

Publication number	Publication date
CA2588966A1 (fr)	2006-06-29
EP2263678A2 (fr)	2010-12-22
CA3087419C (fr)	2023-03-07
CA3087419A1 (fr)	2006-06-29
EP3332789A1 (fr)	2018-06-13
EP4523753A2 (fr)	2025-03-19
EP2805723A1 (fr)	2014-11-26
ES3007339T3 (en)	2025-03-19
SI2805723T1 (en)	2018-02-28
LTPA2018503I1 (lt)	2018-03-12
LT4070800T (lt)	2025-01-10
JP2018165271A (ja)	2018-10-25
EP3332789B1 (fr)	2022-04-06
AR052830A1 (es)	2007-04-04
BRPI0517132B1 (pt)	2020-02-18
KR20070091662A (ko)	2007-09-11
DK2805723T3 (da)	2018-01-29
AU2005318190B2 (en)	2010-11-25
EP1827461A1 (fr)	2007-09-05
EP4523753A3 (fr)	2025-05-28
MX2007007610A (es)	2007-08-03
EP4070800A1 (fr)	2022-10-12
JP2008524313A (ja)	2008-07-10
JP2020193206A (ja)	2020-12-03
EP1827461B1 (fr)	2012-02-29
HUE070333T2 (hu)	2025-05-28
JP6430554B2 (ja)	2018-11-28
HUE059133T2 (hu)	2022-10-28
PL3332789T3 (pl)	2022-08-22
EA015799B1 (ru)	2011-12-30
JP2013216664A (ja)	2013-10-24
EP4070800B1 (fr)	2024-10-16
JP6290962B2 (ja)	2018-03-07
AU2005318190A1 (en)	2006-06-29
BRPI0517132B8 (pt)	2021-05-25
SG160391A1 (en)	2010-04-29
PL2805723T3 (pl)	2018-04-30
FR18C1008I1 (fr)	2018-03-30
LT3332789T (lt)	2022-07-25
US20090081163A1 (en)	2009-03-26
JP2017101061A (ja)	2017-06-08
LTC2805723I2 (lt)	2022-04-25
CY2018006I1 (el)	2018-06-27
LUC00064I2 (fr)	2018-03-28
HUS1800009I1 (hu)	2018-05-02
EP2263678B1 (fr)	2014-06-11
NO20073813L (no)	2007-09-21
JP2015180685A (ja)	2015-10-15
CY2018006I2 (el)	2018-06-27
WO2006067141A1 (fr)	2006-06-29
EP2275110A3 (fr)	2011-04-27
IL212421A (en)	2014-01-30
EA200701221A1 (ru)	2008-02-28
FI4070800T3 (fi)	2025-01-14
CY1119790T1 (el)	2018-06-27
JP6092945B2 (ja)	2017-03-08
CY1112614T1 (el)	2016-02-10
AU2011200768B2 (en)	2012-09-13
JP2016138128A (ja)	2016-08-04
SI4070800T1 (sl)	2025-03-31
US7713947B2 (en)	2010-05-11
IL183930A0 (en)	2007-10-31
US20100203017A1 (en)	2010-08-12
PL4070800T3 (pl)	2025-03-10
PL1827461T3 (pl)	2012-07-31
ES2921858T3 (es)	2022-09-01
US8377903B2 (en)	2013-02-19
BRPI0517132A (pt)	2008-09-30
HRP20120228T1 (hr)	2012-04-30
EP2805723B1 (fr)	2018-01-17
EP2275110B1 (fr)	2013-07-10
JP5795456B2 (ja)	2015-10-14
IL212421A0 (en)	2011-06-30
JP5908863B2 (ja)	2016-04-26
SI3332789T1 (sl)	2022-08-31
LUC00064I1 (fr)	2018-02-14
AU2011200768A1 (en)	2011-03-17
EP2263678A3 (fr)	2011-04-27
EP2275110A2 (fr)	2011-01-19
CA2588966C (fr)	2020-07-21
DK3332789T3 (da)	2022-07-11
DK4070800T3 (da)	2025-01-02

Publication	Publication Date	Title
FR23C1003I2 (fr)	2024-01-12	Compositions et leurs utilisations pour le traitement de la Sclérose en plaques
EP2059210A4 (fr)	2013-01-09	Dispositifs thérapeutiques pour le traitement de divers états chez la femme
EP1931691A4 (fr)	2012-01-11	Inhibiteurs d'odcase pour le traitement du paludisme
EP1838320A4 (fr)	2009-03-18	Antagonistes de cxcr4 pour le traitement de troubles medicaux
EP1951272A4 (fr)	2010-01-27	Utilisation de lactobacillus pour le traitement d'infections virales
EP1985302A4 (fr)	2013-01-02	Médicament pour le traitement de tumeurs et son utilisation
EP2313146A4 (fr)	2015-07-08	Dispositifs pour le traitement d'un anévrysme vasculaire
EP2773643A4 (fr)	2015-07-29	Inhibiteurs de la protéine pak pour le traitement du syndrome de l'x fragile
LTPA2018503I1 (lt)	2018-03-12	Kladribino režimas, skirtas išsėtinei sklerozei gydyti
EP2164501A4 (fr)	2010-07-21	Xylanes sulfatés pour le traitement ou la prophylaxie de maladies respiratoires
PL2205720T3 (pl)	2017-06-30	Kompozycja do leczenia stwardnienia rozsianego
EP2442832A4 (fr)	2013-07-03	Compositions et procédés pour le traitement de la sclérose en plaques
EP2207892A4 (fr)	2010-12-08	Procédés de sélection d'agents actifs pour le traitement du cancer
EP2144632A4 (fr)	2010-08-25	Virus herpes simplex de type 1 synthétiques pour le traitement de cancers
FR2962041B1 (fr)	2012-07-27	Inhibiteurs de la calpaine 3 pour le traitement de dystrophies musculaires et de cardiomyopathies
EP2389180A4 (fr)	2012-08-15	Procédés pour le traitement de dystrophies musculaires
FR2907011B1 (fr)	2010-05-14	Utilisation de la citrulline pour le traitement des etats de denutrition
EP1773970A4 (fr)	2010-08-11	Formules de lubrifiants pour le traitement de toles
EP2015741A4 (fr)	2009-12-23	Inhibiteurs de l'histone desacétylase pour le traitement de la neurodégénération
EP1832861A4 (fr)	2013-01-23	Composant de traitement preanalytique
EP1732549A4 (fr)	2009-11-11	Procedes pour le traitement de synucleinopathies
EP1889618A4 (fr)	2010-11-24	Médicament combiné pour le traitement du diabète
FR2886153B1 (fr)	2009-04-10	Composition destinee au traitement de la sclerose en plaques
EP2099303A4 (fr)	2010-11-10	Compositions à base de tétrahydroisoquinoléine thérapeutiques pour le traitement du cancer
FR2875404B1 (fr)	2008-10-03	Composition pharmaceutique pour le traitement de la rosacee